Literature DB >> 1672694

The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.

K A Cooney1, W C Nichols, M E Bruck, W F Bahou, A D Shapiro, E J Bowie, H R Gralnick, D Ginsburg.   

Abstract

Type IIB von Willebrand Disease (vWD) is characterized by the selective loss of large von Willebrand Factor (vWF) multimers from plasma, presumably due to their increased reactivity with platelets and subsequent clearance from the circulation. Using the PCR, one of a panel of four potential missense mutations was identified in each of the 14 patients studied from 11 unrelated families. None of these substitutions was encountered in a large panel of normal DNAs. These changes all represent C----T transitions at CpG dinucleotides, proposed "hot spots" for mutation in the human genome. The four resulting amino acid substitutions, Arg543----Trp, Arg545----Cys, Val553----Met, and Arg578----Gln, are all clustered within the GpIb binding domain of vWF. Disruption of this latter functional domain may explain the pathogenesis of Type IIB vWD. By sequence polymorphism analysis, the Arg543----Trp substitution was shown to have occurred as at least two independent mutational events. This latter observation, along with the identification of mutations in all 14 patients studied and their localization to the GpIb binding domain, all strongly suggest that these substitutions represent the authentic defects responsible for Type IIB vWD. This panel of mutations may provide a useful diagnostic tool for the majority of patients with Type IIB vWD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672694      PMCID: PMC295141          DOI: 10.1172/JCI115123

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification.

Authors:  H Okayama; D T Curiel; M L Brantly; M D Holmes; R G Crystal
Journal:  J Lab Clin Med       Date:  1989-08

2.  Spontaneous platelet aggregation in type IIB Tampa von Willebrand disease is inhibited by the 52/48-kDa fragment of normal von Willebrand factor, which contains the GPIb binding domain.

Authors:  H I Saba; Y Fujimura; S R Saba; A C Bruce; G A Morelli; Z M Ruggeri; T S Zimmerman
Journal:  Am J Hematol       Date:  1989-03       Impact factor: 10.047

3.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus.

Authors:  U B Gyllensten; H A Erlich
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease.

Authors:  B B Shelton-Inloes; F F Chehab; P M Mannucci; A B Federici; J E Sadler
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

6.  Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

Authors:  J A Dent; S D Berkowitz; J Ware; C K Kasper; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

7.  Investigation of a large kindred with type IIB von Willebrand's disease, dominant inheritance and age-dependent thrombocytopenia.

Authors:  C Mazurier; A Parquet-Gernez; J Goudemand; M F Taillefer; M Goudemand
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

8.  Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.

Authors:  H R Grainick; S B Williams; L P McKeown; M E Rick; P Maisonneuve; C Jenneau; Y Sultan
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.

Authors:  K Y Ngo; V T Glotz; J A Koziol; D C Lynch; J Gitschier; P Ranieri; N Ciavarella; Z M Ruggeri; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets.

Authors:  P G de Groot; A B Federici; H C de Boer; P d'Alessio; P M Mannucci; J J Sixma
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more
  20 in total

1.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

3.  Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; D Lillicrap
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

4.  Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

Authors:  T L Slobodianuk; C Kochelek; J Foeckler; S Kalloway; H Weiler; V H Flood
Journal:  J Thromb Haemost       Date:  2018-12-18       Impact factor: 5.824

Review 5.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

6.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

7.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.

Authors:  M Murata; S R Russell; Z M Ruggeri; J Ware
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.